Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has received a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports.

BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

(MENAFN- GlobeNewsWire - Nasdaq) BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab, but analysts believe the selloff was an overreaction. Atacicept is more disease-modifying, while ...

BRISBANE, Calif. - Vera Therapeutics , Inc. (NASDAQ:VERA), a late-stage biotechnology company with a market capitalization of $1.7 billion, is on schedule to announce primary endpoint results from ...